Post-earnings recap
Reported
Thu, Aug 1, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.44 per share, but no revenue figures were provided. The stock reacted negatively, declining by 2.05%. The lack of guidance and details from the earnings call may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.